Avalon Ventures Gets Exit At Sitari Pharmaceuticals
socalTECH
SEPTEMBER 11, 2019
San Diego-based biotech investor Avalon Ventures has scored an exit, saying late Tuesday evening that it has entered into a definitive agreement with GlaxoSmithKline (GSK), to sell Sitari Pharmaceuticals to GSK. According to Avalon Ventures, Sitari was the very first company to be formed under the GSK-Avalon venture collaboration, in 2013.
Let's personalize your content